Polymorphisms of TP53 codon 72 with breast carcinoma risk: Evidence from 12226 cases and 10782 controls

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Zhuo, Wenlei ^a   Zhang, Yunsong ^b   Xiang, Zhaolan ^a   Cai, Lei ^a   Chen, Zhengtang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chinese PLA 254 Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; BREAST CARCINOMA; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CODON; GENE FREQUENCY; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; BREAST TUMOR; CARCINOMA; CASE CONTROL STUDY; CHEMISTRY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MEDLINE; RISK FACTOR;

BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDLINE; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 69549101616     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-115     Document Type: Article

References (72)

1. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. C Kahlenborn F Modugno DM Potter WB Severs, Mayo Clin Proc 2006 81 1290 1302 10.4065/81.10.1290 17036554
2. Obesity and prognosis of breast cancer. AR Carmichael, Obes Rev 2006 7 333 340 10.1111/j.1467-789X.2006.00261.x 17038127 (Pubitemid 44564304)
3. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. MJ Gunter DR Hoover H Yu S Wassertheil-Smoller TE Rohan JE Manson J Li GY Ho X Xue GL Anderson RC Kaplan TG Harris BV Howard J Wylie-Rosett RD Burk HD Strickler, J Natl Cancer Inst 2009 101 48 60 19116382
4. Family history and the risk of breast cancer: a systematic review and meta-analysis. PD Pharoah NE Day S Duffy DF Easton BA Ponder, Int J Cancer 1997 71 800 809 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B 9180149
5. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. C Tang N Chen M Wu H Yuan Y Du, Breast Cancer Res Treat 2009 19145484
6. Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. M Saadat M Ansari-Lari, Breast Cancer Res Treat 2008 doi: 10.1007/s10549-008-0051-0
7. Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. E Zintzaras, Clin Genet 2006 69 327 36 10.1111/j.1399-0004.2006.00605.x 16630166
8. Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk. AM González-Zuloeta Ladd AA Vásquez F Rivadeneira C Siemes A Hofman BH Stricker HA Pols AG Uitterlinden CM van Duijn, Breast Cancer Res Treat 2008 107 415 419 10.1007/s10549-007-9562-3 17453340 (Pubitemid 351172114)
9. Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review. LF Masson L Sharp SC Cotton J Little, Am J Epidemiol 2005 161 901 915 10.1093/aje/kwi121 15870154 (Pubitemid 40656412)
10. Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Y Zhang PA Newcomb KM Egan L Titus-Ernstoff S Chanock R Welch LA Brinton J Lissowska A Bardin-Mikolajczak B Peplonska N Szeszenia-Dabrowska W Zatonski M Garcia-Closas, Cancer Epidemiol Biomarkers Prev 2006 15 353 358 10.1158/1055-9965.EPI-05-0653 16492928 (Pubitemid 43342187)
11. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. K Bumroongkit B Rannala P Traisathit M Srikummool Y Wongchai D Kangwanpong, Cancer Genet Cytogenet 2008 185 20 27 10.1016/j.cancergencyto.2008.04.009 18656689 (Pubitemid 352010359)
12. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. JG Assumpção AL Seidinger MJ Mastellaro RC Ribeiro GP Zambetti R Ganti K Srivastava S Shurtleff D Pei LC Zeferino RM Dufloth SR Brandalise JA Yunes, BMC Cancer 2008 8 357 10.1186/1471-2407-8-357 19046423
13. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations. M Mahdavinia F Bishehsari F Verginelli A Cumashi R Lattanzio M Sotoudeh R Ansari D Semeraro M Hormazdi H Fakheri N Rakhshani L De Lellis MC Curia A Cama M Piantelli R Malekzadeh S Iacobelli R Mariani-Costantini, J Cell Physiol 2008 216 543 550 10.1002/jcp.21428 18330889 (Pubitemid 351898483)
14. Codon 72 polymorphism of the TP53 gene. S Ara PS Lee MF Hansen H Saya, Nucleic Acids Res 1990 18 4961 10.1093/nar/18.16.4961 1975675
15. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. H Shen A Solari X Wang Z Zhang Y Xu L Wang X Hu J Guo Q Wei, Oncol Rep 2004 11 1115 1120 15069555
16. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. A Storey M Thomas A Kalita C Harwood D Gardiol F Mantovani J Breuer IM Leigh G Matlashewski L Banks, Nature 1998 393 229 234 10.1038/30400 9607760 (Pubitemid 28261713)
17. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. YC Wang HS Lee SK Chen YY Chang CY Chen, Eur J Cancer 1999 35 226 230 10.1016/S0959-8049(98)00369-4 10448264 (Pubitemid 29136772)
18. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. MW Yu SY Yang YH Chiu YC Chiang YF Liaw CJ Chen, Hepatology 1999 29 697 702 10.1002/hep.510290330 10051470
19. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. I Mabrouk S Baccouche R El-Abed R Mokdad-Gargouri A Mosbah S Sad J Daoud M Frikha R Jlidi A Gargouri, Ann N Y Acad Sci 2003 1010 764 770 10.1196/annals.1299.137 15033824 (Pubitemid 38265078)
20. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Y Zhou N Li W Zhuang GJ Liu TX Wu X Yao L Du ML Wei XT Wu, Int J Cancer 2007 121 1481 1486 10.1002/ijc.22833 17546594 (Pubitemid 47328706)
21. Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. AS Khayat L Lobo Gatti E Moura Lima PP de Assumpção FJ Nascimento Motta ML Harada C Casartelli SL Marques Payão MA Cardoso Smith RR Burbano, Clin Exp Med 2005 5 161 168 10.1007/s10238-005-0081-4 16362795 (Pubitemid 41813759)
22. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. MR Munaf TG Clark J Flint, Psychiatry Res 2004 129 39 44 10.1016/j.psychres.2004.06.011 15572183 (Pubitemid 39574435)
23. Bias in meta-analysis detected by a simple, graphical test. M Egger G Davey Smith M Schneider C Minder, BMJ 1997 315 629 634 9310563
24. The "file drawer problem" and tolerance for null results. R Rosenthal, Psychol Bull 1979 86 638 641 10.1037/0033-2909.86.3.638
25. Study of p53 codon 72 polymorphism in patients with breast cancer. JO Vieira ID da Silva PE Higo NC Nogueira-de-Souza LH Gebrim, Eur J Gynaecol Oncol 2008 29 364 367 18714570
26. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. M Bonafé C Ceccarelli F Farabegoli D Santini M Taffurelli C Barbi E Marzi C Trapassi G Storci F Olivieri C Franceschi, Clin Cancer Res 2003 9 4860 4864 14581358
27. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Y Xu L Yao T Ouyang J Li T Wang Z Fan B Lin Y Lu Y Xie, Clin Cancer Res 2005 11 7328 7333 10.1158/1078-0432.CCR- 05-0507 16243804 (Pubitemid 41507691)
28. Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. MM Siddique C Balram L Fiszer-Maliszewska A Aggarwal A Tan P Tan KC Soo K Sabapathy, Cancer Epidemiol Biomarkers Prev 2005 14 2245 2252 10.1158/1055-9965.EPI-05-0153 16172238 (Pubitemid 41603274)
29. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. T Toyama Z Zhang M Nishio M Hamaguchi N Kondo H Iwase H Iwata S Takahashi H Yamashita Y Fujii, Breast Cancer Res 2007 9 R34 10.1186/bcr1682 17537232 (Pubitemid 350215173)
30. Possible difference in frequencies of genetic polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between estrogen receptor-positive and -negative breast cancers. M Hamaguchi M Nishio T Toyama H Sugiura N Kondo Y Fujii H Yamashita, Jpn J Clin Oncol 2008 38 734 742 10.1093/jjco/hyn097 18820009
31. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. I Vannini W Zoli A Tesei M Rosetti P Sansone G Storci A Passardi I Massa M Ricci D Gusolfino F Fabbri P Ulivi G Brigliadori D Amadori M Bonafe, Tumour Biol 2008 29 145 151 10.1159/000143400 18612219
32. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. SS Lum HW Chua H Li WF Li N Rao J Wei Z Shao K Sabapathy, Carcinogenesis 2008 29 754 761 10.1093/carcin/bgn024 18281248
33. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. M Kyndi J Alsner LL Hansen FB Sørensen J Overgaard, Acta Oncol 2006 45 602 609 10.1080/ 02841860600660811 16864176 (Pubitemid 44167213)
34. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. B Ogretmen AR Safa, Oncogene 1997 14 499 506 10.1038/sj.onc. 1200855 9053847
35. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. A Langerød IR Bukholm A Bregrd PE Lønning TI Andersen TO Rognum GI Meling RA Lothe AL Børresen-Dale, Cancer Epidemiol Biomarkers Prev 2002 11 1684 1688 12496062
36. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. A Weston JH Godbold, Environ Health Perspect 1997 105 Suppl 4 919 926 10.2307/3433304 9255581
37. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. EN Papadakis DN Dokianakis DA Spandidos, Mol Cell Biol Res Commun 2000 3 389 392 10.1006/mcbr.2000.0241 11032762 (Pubitemid 30803131)
38. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. C Noma Y Miyoshi T Taguchi Y Tamaki S Noguchi, Cancer Lett 2004 210 197 203 10.1016/j.canlet.2004.03.031 15183535 (Pubitemid 38748690)
39. The R72P P53 mutation is associated with familial breast cancer in Jewish women. T Ohayon R Gershoni-Baruch MZ Papa T Distelman Menachem S Eisenberg Barzilai E Friedman, Br J Cancer 2005 92 1144 1148 10.1038/sj.bjc.6602451 15756275 (Pubitemid 40546682)
40. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. AP Damin AP Frazzon DC Damin A Roehe V Hermes C Zettler CO Alexandre, Cancer Detect Prev 2006 30 523 529 10.1016/j.cdp.2006.09.007 17113725 (Pubitemid 44828290)
41. Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. S Costa D Pinto D Pereira H Rodrigues J Cameselle-Teijeiro R Medeiros F Schmitt, BMC Cancer 2008 8 32 10.1186/1471-2407-8-32 18230179 (Pubitemid 351314953)
42. p53 polymorphisms and haplotypes in breast cancer. A Själander R Birgander G Hallmans S Cajander P Lenner L Athlin G Beckman L Beckman, Carcinogenesis 1996 17 1313 1316 10.1093/carcin/17.6.1313 8681448 (Pubitemid 26196343)
43. p53 haplotype determination in breast cancer. A Weston CF Pan HB Ksieski S Wallenstein GS Berkowitz PI Tartter IJ Bleiweiss ST Brower RT Senie MS Wolff, Cancer Epidemiol Biomarkers Prev 1997 6 105 112 9037561
44. p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. T Li ZM Lu M Guo QJ Wu KN Chen HP Xing Q Mei Y Ke, Cancer 2002 95 2571 2576 10.1002/cncr.11008 12467072 (Pubitemid 35424044)
45. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. S Wang-Gohrke H Becher R Kreienberg IB Runnebaum J Chang-Claude, Pharmacogenetics 2002 12 269 272 10.1097/00008571-200204000-00012 11927843 (Pubitemid 34596792)
46. P53 codon 72 polymorphism in breast cancer. N Buyru H Tigli N Dalay, Oncol Rep 2003 10 711 714 12684648
47. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. XE Huang N Hamajima N Katsuda K Matsuo K Hirose M Mizutani H Iwata S Miura J Xiang S Tokudome K Tajima, Breast Cancer 2003 10 307 311 10.1007/BF02967650 14634508
48. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. S Katiyar BK Thelma NS Murthy S Hedau N Jain V Gopalkrishna SA Husain BC Das, Mol Cell Biochem 2003 252 117 124 10.1023/A:1025546610920 14577584 (Pubitemid 37220740)
49. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. I Mabrouk S Baccouche R El-Abed R Mokdad-Gargouri A Mosbah S Sad J Daoud M Frikha R Jlidi A Gargouri, Ann N Y Acad Sci 2003 1010 764 770 10.1196/annals.1299.137 15033824 (Pubitemid 38265078)
50. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. TG Kalemi AF Lambropoulos M Gueorguiev S Chrisafi KT Papazisis A Kotsis, Cancer Lett 2005 222 57 65 10.1016/j.canlet.2004.11.025 15837541 (Pubitemid 40544847)
51. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. J Tommiska H Eerola M Heinonen L Salonen M Kaare J Tallila A Ristimäki K von Smitten K Aittomäki P Heikkilä C Blomqvist H Nevanlinna, Clin Cancer Res 2005 11 5098 5103 10.1158/1078-0432.CCR-05-0173 16033823 (Pubitemid 41003693)
52. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. C Baynes CS Healey KA Pooley S Scollen RN Luben DJ Thompson PD Pharoah DF Easton BA Ponder AM Dunning SEARCH breast cancer study, Breast Cancer Res 2007 9 2 R27 10.1186/bcr1669 17428325 (Pubitemid 350215160)
53. Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. S Gochhait SI Bukhari N Bairwa S Vadhera K Darvishi M Raish P Gupta SA Husain RN Bamezai, Breast Cancer Res 2007 9 R71 10.1186/bcr1780 17945002
54. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. B Khadang MJ Fattahi A Talei AS Dehaghani A Ghaderi, Cancer Genet Cytogenet 2007 173 38 42 10.1016/j.cancergencyto.2006.09.010 17284368 (Pubitemid 46187296)
55. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. MK Schmidt S Reincke A Broeks LM Braaf FB Hogervorst RA Tollenaar N Johnson O Fletcher J Peto J Tommiska C Blomqvist HA Nevanlinna CS Healey AM Dunning PD Pharoah DF Easton T Dörk LJ Van't Veer Breast Cancer Association Consortium, Cancer Res 2007 67 19 9584 9590 10.1158/0008-5472.CAN-07-0738 17909070 (Pubitemid 47535950)
56. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. BL Sprague A Trentham-Dietz M Garcia-Closas PA Newcomb L Titus-Ernstoff JM Hampton SJ Chanock JL Haines KM Egan, Carcinogenesis 2007 28 1680 1686 10.1093/carcin/bgm097 17449902 (Pubitemid 47289028)
57. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. M Akkiprik O Sonmez BM Gulluoglu HB Caglar H Kaya P Demirkalem U Abacioglu M Sengoz A Sav A Ozer, Pathol Oncol Res 2008 DOI:10.1007/s12253-008-9129-6. 19048399
58. Association of p53 polymorphisms and its haplotypes with susceptibility of breast cancer. W Zhang MJ Jin K Chen, Zhejiang Da Xue Xue Bao Yi Xue Ban 2007 36 561 566 18067229
59. Assessing the influence of a single study in the meta-analysis estimate. A Tobias, Stata Techn Bull 1999 8 15 17
60. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. A Koushik RW Platt EL Franco, Cancer Epidemiol Biomarkers Prev 2004 13 11 22 10.1158/1055-9965.EPI-083-3 14744727 (Pubitemid 38116615)
61. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. SH Jee SY Won JE Yun JE Lee JS Park SS Ji, Int J Gynaecol Obstet 2004 85 301 308 10.1016/j.ijgo.2003.08.017 15145278 (Pubitemid 38622573)
62. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. H Sousa AM Santos D Pinto R Medeiros, Int J Mol Med 2007 20 731 741 17912468
63. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. A Matakidou T Eisen RS Houlston, Mutagenesis 2003 18 377 85 10.1093/mutage/geg008 12840112 (Pubitemid 36850206)
64. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Y Zhou N Li W Zhuang GJ Liu TX Wu X Yao L Du ML Wei XT Wu, Int J Cancer 2007 121 1481 1486 10.1002/ijc.22833 17546594 (Pubitemid 47328706)
65. A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: Evidence from 15,857 subjects. Y Li LX Qiu XK Shen XJ Lv XP Qian Y Song, Lung Cancer 2009
66. Polymorphisms in the p53 pathway. EC Pietsch O Humbey ME Murphy, Oncogene 2006 25 1602 1611 10.1038/sj.onc.1209367 16550160
67. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. P Dumont JI Leu AC Della Pietra 3rd DL George M Murphy, Nat Genet 2003 33 357 365 10.1038/ng1093 12567188 (Pubitemid 36278852)
68. The proline form of p53 codon 72 polymorphism is associated with endometriosis. CC Chang YY Hsieh FJ Tsai CH Tsai HD Tsai CC Lin, Fertil Steril 2002 77 43 45 10.1016/S0015-0282(01)02938-7 11779589 (Pubitemid 34093891)
69. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. J Koshiol L Lindsay JM Pimenta C Poole D Jenkins JS Smith, Am J Epidemiol 2008 168 123 137 10.1093/aje/kwn036 18483125 (Pubitemid 351951589)
70. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. CS Miller BM Johnstone, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 91 622 635 10.1067/moe.2001.115392 11402272 (Pubitemid 33601674)
71. The possible involvement of virus in breast cancer. MK Amarante MA Watanabe, J Cancer Res Clin Oncol 2009 135 329 337 10.1007/s00432-008-0511-2 19009309
72. Meta-analysis of genetic association studies. MR Munaf J Flint, Trends Genet 2004 20 9 439 444 10.1016/j.tig.2004.06.014 15313553 (Pubitemid 39094573)